2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2113

Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Abstract Number: 2596

Less Musculoskeletal Ultrasound Power Doppler Activity Seen in Obese Rheumatoid Arthritis
Abstract Number: 1085

Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis
Abstract Number: 334

Lifetime Risk of Symptomatic Hand Osteoarthritis: The Johnston County Osteoarthritis Project
Abstract Number: 135

Limitations of Treat-to-Target in Rheumatoid Arthritis: Joint Damage Appears As Severe As Inflammation in Contemporary Care at One Site
Abstract Number: 1508

Lipid Target Achievement Among Patients with Recent-Onset Rheumatoid Arthritis during the First Six Years of Follow-up: Results from a French Multicenter Cohort of Early Arthritis
Abstract Number: 1788

Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 2336

Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 2152

Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases
Abstract Number: 3041

Long Term Biological Therapy in Uveitis Refractory Due to Behçet’s Disease. Multicenter Study of 165 Patients.
Abstract Number: 2049

Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases
Abstract Number: 406

Long Term Follow up of Inner City Pediatric Patients with Lupus Nephritis
Abstract Number: 3069

Long Term Follow-up Results of Endovascular Repair in the Management of Arterial Stenosis Caused By Takayasu Arteritis
Abstract Number: 1396

Long Term Outcome of Neurosarcoidosis
Abstract Number: 2195

Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].